克莱德
聚糖
人类免疫缺陷病毒(HIV)
抗体
病毒学
包络线(雷达)
生物
计算生物学
遗传学
基因
糖蛋白
系统发育学
计算机科学
电信
雷达
作者
Mrinal Arandhara,Yogendra Kumar,Narendra M. Dixit,Prabal K. Maiti
标识
DOI:10.1021/acs.jcim.5c01051
摘要
N-linked glycans are important in the elicitation and activity of many broadly neutralizing antibodies (bNAbs) against HIV-1. The high conformational flexibility of glycans hindered detailed atomistic investigations of glycan-bNAb interactions, including the glycan shielding of bNAbs. Importantly, how these interactions vary across different HIV-1 clades remains unclear. The variability in the number and location of potential N-linked glycosylation sites (PNGS) on the HIV-1 envelope (Env) protein across clades can lead to differences in glycan dynamics and topology, potentially affecting Env-bNAb interactions and the clade-specific efficacy of bNAb-based therapies. Here, we combined comprehensive glycan conformational sampling, using the software glycoSHIELD, and molecular dynamics simulations to model fully glycosylated trimeric Env for six HIV-1 strains, one from each of the major clades A, B, C, G, CRF01 AE (01 AE), and CRF07 BC (07 BC). We assessed the interactions of 50 different bNAbs, drawn from all of the major bNAb classes, with each of these strains, quantifying glycan shielding, glycan-bNAb interactions, and their clade-specific variations for each bNAb in microscopic detail. Our findings reveal that while glycans cover most of the exposed surface area in all clades, the amount of accessible surface varies, with clade B having the minimum and clade 07 BC having the maximum antibody accessible surface area. The number of glycan conformers per glycosylation site also varies with clades, even for conserved sites. Overall, we observed that bNAbs interact with more glycans than those previously reported in experimental and computational studies. Important variations emerge in Env-bNAb interactions with the clade and bNAb-class. These atomic-level insights will be valuable for improving bNAb-based therapies and vaccine design strategies against HIV-1.
科研通智能强力驱动
Strongly Powered by AbleSci AI